Arvinas Taps Insider Randy Teel as CEO Amid Critical Pipeline Milestones
Event summary
- Randy Teel, Ph.D., promoted to President and CEO of Arvinas, effective February 12, 2026, succeeding John Houston, Ph.D.
- Teel previously served as Chief Business Officer and played key roles in Arvinas’ IPO and strategic partnerships.
- John Houston transitions to consulting role after nine years as CEO, overseeing $2B in funding and first positive pivotal trial results.
- Briggs Morrison, M.D., elected as new Chair of Arvinas’ Board of Directors.
- Arvinas highlights upcoming clinical data milestones for LRRK2, BCL6, and KRAS G12D degraders.
The big picture
Arvinas’ appointment of Randy Teel as CEO underscores a strategic shift toward leveraging its PROTAC platform for transformative therapies. The move comes as the company prepares to report critical clinical data for its pipeline, including programs targeting neurodegenerative disorders and cancers. Teel’s deep industry experience and internal knowledge position him to navigate the biotech’s next growth phase, though sustaining innovation will be key amid a competitive landscape.
What we're watching
- Pipeline Execution
- How Arvinas will advance its earlier-stage clinical programs following the first successful pivotal trial of a PROTAC degrader.
- Leadership Transition
- Whether Randy Teel can sustain the momentum built under John Houston’s leadership, particularly in securing partnerships and funding.
- Market Differentiation
- The pace at which Arvinas can maintain its lead in targeted protein degradation amid competitive pressures.
Related topics